Cargando…

A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse

Fabry disease is a rare lysosomal storage disorder resulting from the lack of α-Gal A gene activity. Globotriaosylceramide (GB3, ceramide trihexoside) is a novel endogenous biomarker which predicts the incidence of Fabry disease. At the early stage efficacy/biomarker study, a rapid method to determi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Seok-Ho, Park, Min-Ho, Byeon, Jin-Ju, Lee, Byeong ill, Park, Yuri, Ko, Ah-ra, Seong, Mi-ran, Lee, Soyeon, Kim, Mi Ra, Seo, Jinwook, Jung, Myung Eun, Jin, Dong-Kyu, Shin, Young G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027126/ https://www.ncbi.nlm.nih.gov/pubmed/29880732 http://dx.doi.org/10.3390/pharmaceutics10020069

Ejemplares similares

Qualification and Application of a Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometric Method for the Determination of Adalimumab in Rat Plasma
por: Park, Yuri, et al.
Publicado: (2018)

Qualification and application of liquid chromatography-quadrupole time-of-flight mass spectrometric method for the determination of carisbamate in rat plasma and prediction of its human pharmacokinetics using physiologically based pharmacokinetic modeling
por: Lee, Byeong ill, et al.
Publicado: (2020)

Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
por: Park, Min-Ho, et al.
Publicado: (2019)

Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
por: Shin, Seok-Ho, et al.
Publicado: (2018)

Investigation of In Vitro and In Vivo Metabolism of α-Amanitin in Rats Using Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometric Method
por: Lee, Jiyu, et al.
Publicado: (2022)

Assessments of the In Vitro and In Vivo Linker Stability and Catabolic Fate for the Ortho Hydroxy-Protected Aryl Sulfate Linker by Immuno-Affinity Capture Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometric Assay
por: Lee, Byeong ill, et al.
Publicado: (2021)

Quantification and Metabolite Identification of Sulfasalazine in Mouse Brain and Plasma Using Quadrupole-Time-of-Flight Mass Spectrometry
por: Choi, Jangmi, et al.
Publicado: (2021)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease
por: Ishii, Satoshi, et al.
Publicado: (2020)

Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
por: Tsukimura, Takahiro, et al.
Publicado: (2021)

Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease
por: Taguchi, Atsumi, et al.
Publicado: (2023)

Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography–Mass Spectrometric Method
por: Park, Yuri, et al.
Publicado: (2020)

Profiling and Identification of Omeprazole Metabolites in Mouse Brain and Plasma by Isotope Ratio-Monitoring Liquid Chromatography-Mass Spectrometric Method
por: Shin, Seok-Ho, et al.
Publicado: (2020)

Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion
por: Kamani, Mustafa A, et al.
Publicado: (2016)

Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy
por: Gaggl, Martina, et al.
Publicado: (2016)

Serum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea
por: Kim, Jeong-Yup, et al.
Publicado: (2010)

Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
por: Shiga, Tomoko, et al.
Publicado: (2021)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling
por: Lee, Byeong ill, et al.
Publicado: (2019)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy
por: Liguori, Rocco, et al.
Publicado: (2017)

Ceria-Zirconia nanoparticles reduce intracellular globotriaosylceramide accumulation and attenuate kidney injury by enhancing the autophagy flux in cellular and animal models of Fabry disease
por: An, Jong Hun, et al.
Publicado: (2022)

One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease
por: Najafian, Behzad, et al.
Publicado: (2016)

Quantitative Analysis of Daporinad (FK866) and Its In Vitro and In Vivo Metabolite Identification Using Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
por: Park, Minjae, et al.
Publicado: (2022)

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
por: Duro, Giovanni, et al.
Publicado: (2018)

Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types
por: Welford, R W D, et al.
Publicado: (2018)

Spontaneous Accumulation of Globotriaosylceramide (Gb3) in Proximal Renal Tubules in an ICR Mouse
por: Mutsuga, Mayu, et al.
Publicado: (2013)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
por: Mauer, Michael, et al.
Publicado: (2017)

MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease
por: Maier, Nadine, et al.
Publicado: (2021)

Fabry cardiomyopathy: Gb3‐induced auto‐reactive panmyocarditis requiring heart transplantation
por: Frustaci, Andrea, et al.
Publicado: (2020)

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
por: Nowak, Albina, et al.
Publicado: (2022)

Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease
por: Nikolaenko, Valeria, et al.
Publicado: (2023)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Pathologic findings of Fabry nephropathy: the pivotal role of kidney biopsy
por: Shin, Jung-ho, et al.
Publicado: (2021)

Short-Term Efficacy of Enzyme Replacement Therapy in Korean Patients with Fabry Disease
por: Choi, Jin-Ho, et al.
Publicado: (2008)

A Case of Fabry's Disease with Congenital Agammaglobulinemia
por: Lee, Ki-Yeol, et al.
Publicado: (2011)

Circulating Anti-GB3 Antibody as a Biomarker of Myocardial Inflammation in Patients with Fabry Disease Cardiomyopathy
por: Frustaci, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_07b5tn6bve2c1pbsafof0hg1sa